Genentech Files sBLA for Avastin for First-Line NSCLC Treatment

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 5
Volume 15
Issue 5

Genentech Files sBLA for Avastin for First-Line NSCLC Treatment

SOUTH SAN FRANCISCO—Genentech Inc. has submitted a supplemental Biologics License Application (sBLA) to FDA for bevacizumab (Avastin) in combination with platinum-based chemotherapy for first-line treatment of advanced, non-squamous, non-small-cell lung cancer (NSCLC). The company has requested priority review on the submission. In a phase III trial (E4599) in patients with locally advanced, metastatic, or recurrent NSCLC, Avastin plus paclitaxel and carboplatin improved overall survival by 25%, compared with chemotherapy alone.

Recent Videos
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.